Zhang Xuemei, Wang Yadi, Tang Yujie, Wei Ran, Zhao Runze, Yu Zhenhai, Lu Chao
Department of Reproductive Medicine, Affiliated Hospital of Shandong Second Medical University, Weifang 261000, China; School of Clinical Medicine, Shandong Second Medical University, Weifang 261000, China.
Department of Reproductive Medicine, Affiliated Hospital of Shandong Second Medical University, Weifang 261000, China; School of Clinical Medicine, Shandong Second Medical University, Weifang 261000, China.
Biochim Biophys Acta Mol Cell Res. 2025 Oct;1872(7):120009. doi: 10.1016/j.bbamcr.2025.120009. Epub 2025 Jun 16.
Endometriosis (EM), a gynecologic disorder affecting 10 % of childbearing age women, with complex pathogenesis involving cell proliferation and metabolic abnormalities similar to malignancies. Unusual expression of key enzymes and regulators in glycolysis pathway contributes to the development of endometriosis. Phosphoglycerate kinase 1 (PGK1) was a key enzyme in glycolysis with additional roles as a transcription factor co-activator and protein kinase. We discovered that PGK1 was elevated and associated strongly with the development of EM. The PGK1 inhibitor NG52 inhibited the growth of endometriosis lesions in mice by preventing cell migration and proliferation. Furthermore, we found that DNA damage response 4 (DDIT4) was a new downstream target gene of PGK1. PGK1 regulated the nuclear translocation of DDIT4. Additionally, we also observed that PGK1 up-regulate the transcriptional activity of DDIT4, leading to DDIT4 overexpression that promoted the development of endometriosis. These findings may provide new insights for potential non-hormonal targeted therapies for endometriosis treatment.
子宫内膜异位症(EM)是一种影响10%育龄妇女的妇科疾病,其发病机制复杂,涉及细胞增殖和类似于恶性肿瘤的代谢异常。糖酵解途径中关键酶和调节因子的异常表达有助于子宫内膜异位症的发展。磷酸甘油酸激酶1(PGK1)是糖酵解中的关键酶,还作为转录因子共激活因子和蛋白激酶发挥额外作用。我们发现PGK1升高且与EM的发展密切相关。PGK1抑制剂NG52通过阻止细胞迁移和增殖来抑制小鼠子宫内膜异位症病变的生长。此外,我们发现DNA损伤反应4(DDIT4)是PGK1的一个新的下游靶基因。PGK1调节DDIT4的核转位。此外,我们还观察到PGK1上调DDIT4的转录活性,导致DDIT4过表达,从而促进子宫内膜异位症的发展。这些发现可能为子宫内膜异位症治疗的潜在非激素靶向治疗提供新的见解。